| |
|
|
| VESIcare®(conivaptan) |
|
|
|
| NDC Number |
Product Number |
Desc
ription |
Strength |
Concen
tration |
Size |
Unit of Sale |
Closure |
| 51248-151-01 |
15101 |
Round film coated tablets |
5 or 10mg |
5 or 10mg |
5 or 10mg |
Bottle of 30 |
NA |
| 51248-151-03 |
15103 |
Round film coated tablets |
5 or 10mg |
5 or 10mg |
5 or 10mg |
Bottle of 90 |
NA |
| 51248-151-52 |
15152 |
Round film coated tablets |
5 or 10mg |
5 or 10mg |
5 or 10mg |
Pack of 100 |
NA |
|
|
| Each mL contains: |
| Solifenacin succinate |
5 or 10 mg |
| Inactive ingredients |
| Lactose monohydrate |
| Corn starch |
| Hypromellose 2910 |
| Magnesium stearate |
| talc |
| Plyethylene glycol 8000 |
| Titanium dioxide with yellow ferric oxide in 5 mg tablet |
| Titanium dioxide with red ferric oxide in 10 mg table |
|
|
VESIcare® is a registered trademark of Astellas Pharmaceuticals Inc. VESIcare® is co-promoted with GlaxoSmithKline in the U.S. |
|
|
|
|
